About Us

Priv.Doz.Dr.med. Hans-Åke Fabricius      IMG 8777 pass

 

CVO of Cell Receptor, discoverer of the new mechanism regulating cell growth,  product developer and scientific advisor to Cell Receptor, was born in Finland in 1945. He studied medicine in Tübingen and there he made his state examination as a physician and his doctorate at the Max Planck Institut für Virusforschung there where he worked in the field of tumor biology. In 1973 he worked as an IARC scholarship holder at the Wallenberg Laboratory in Uppsala. 1981 he completed his training for specialist in Laboratory Medicine in Freiburg, where he 1982 received his Venia Legendi for Laboratory Medicine and Clinical Chemistry with his discovery of a T-cell Growth factor that later was named Interleukin II.

He has with his group received 12 cell-biological patents and is the author / co-author of more than 50 scientific papers and contributions.

In 1991 he joined the Krankenhaus Am Urban in Berlin as chief physician of the central laboratory. From 1996 to 1999 he was Medical Director of the Urban Krankenhaus, and from 2001 he built the central laboratory Institute for the Vivantes Netzwerk für Gesundheit. At the beginning of this activity, the hospital laboratories in the municipal clinics in Berlin employed 321 persons. After the restructuring, 172 persons were sufficient to handle the task. The institute has since grown to be the largest hospital-based medical laboratory in Germany.

He went 2008 into retirement and was from 1996 to 2017 active as an expert witness and forensic genetics consultant for kinship testing in Berlin. Since 2010, he is active again in the experimental biology of tumor cells, and is particularly concerned with regulatory mechanisms of cell growth.

He is particularly interested in the mechanisms of transfer of growth signals from the site of their synthesis to growth committed tumor cells. His new discoveries, are now in the possession of Cell Receptor and will make a significant contribution to combating metastatic seeding.

 

Béatrice Fabricius                                      IMG 0031det

 

Béatrice Fabricius is our founder and CEO. She was born in Bern, Switzerland, in 1955, moved to Germany in 1965 and spent time abroad in Chicago during her high school years in Wolfsburg. She studied graphic and textile design in Hanover and then pursued an independent career, establishing design galleries in Braunschweig, Hamburg and later in Berlin, where she also owned and operated a small five-star hotel, Villa Ammonit, that belonged to the group of Great Small Hotels. In 2014, she founded a private laboratory for forensic genetics there, which also housed the Cell Receptor research laboratory managed by her husband. In 2017, she restructured Cell Receptor into the current public company, which now holds 4 medical process patents resulting from his research, and is determined to introduce the use of these into clinical oncology.

 

 ---------------------------------

Patents by Inventor Hans-Åke Fabricius

Hans-Åke Fabricius has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

• Regulatory glycoprotein for immune response and the use, thereof in the production of T-cell growth factor
Patent number: 5093479
Abstract: An interleukin-1 preparation is obtained as a supernatant by cell culturing human peripheral mononuclear blood cells.
Type: Grant
Filed: October 11, 1988
Date of Patent: March 3, 1992
Inventors: Hans-Åke Fabricius, Eckart Köttgen

• Method of preventing T-cell blastogenesis
Patent number: 4808533
Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed.
Type: Grant
Filed: May 3, 1985
Date of Patent: February 28, 1989
Inventors: Hans-Åke Fabricius, Eckart U. Köttgen

• Process for producing an Interleukin-1 preparation
Patent number: 4681844
Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed.
Type: Grant
Filed: May 3, 1985
Date of Patent: July 21, 1987
Inventors: Hans-Åke Fabricius, Eckart U. Köttgen

• Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
Patent number: 4661447
Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed.
Type: Grant
Filed: July 15, 1983
Date of Patent: April 28, 1987
Inventors: Hans-Åke Fabricius, Eckart U. Köttgen

• Serum-free and mitogen-free T-cell growth factor and process for making same
Patent number: 4464355
Abstract: A serum-free and mitogen-free T-cell growth factor which is effective in stimulating natural killer cell function in tumor patients is provided. A method of producing the growth factor from human, bovine or porcine spleen or blood is described.
Type: Grant
Filed: September 3, 1982
Date of Patent: August 7, 1984
Inventors: Hans-Åke Fabricius, Roland Stahn

• High yield process for in vitro production of serum-free and mitogen-free interleukin-2
Patent number: 4448879
Abstract: An improved in vitro cell culture process for producing in high yield and purity a serum-free and mitogen-free interleukin-2-containing conditioned supernatant.
Type: Grant
Filed: September 15, 1982
Date of Patent: May 15, 1984
Inventors: Hans-Åke Fabricius, Roland Stahn

• Regulatory glycoprotein for immune response and the use thereof in the production of T-cell growth factor
Patent number: 4406830
Abstract: A cell mediated immune response system glycoprotein having a molecular weight of about 90,000 and having at least one sialic acid moiety as a biologically active site is disclosed.
Type: Grant
Filed: April 17, 1981
Date of Patent: September 27, 1983
Inventors: Hans-Åke Fabricius, Eckart U. Köttgen

• Process for suppressing graft rejection in organ transplantation
Patent number: 4388309
Abstract: Suppression of the immunological rejection mechanism of a host which has received an organ transplant in achieved by the daily administration to the host of a ganglioside agent which effectively blocks the soluble immunological cell mediator interleukin 2 and /or a blastogenic factor.
Type: Grant
Filed: June 10, 1981
Date of Patent: June 14, 1983
Inventors: Hans-Åke Fabricius, Eckart U. Köttgen

Europe:

* SULFATED POLYSACCHARIDES FOR USE IN THE TREATMENT OF CANCER
Patent number: EP 3 060 223 B1

Date of publication 30.08.2017
Inventor: Hans-Åke Fabricius
Description: The invention relates to a method for modulating the growth and/or proliferation of mammalian cells by modulating the physical interaction between platelets (thrombocytes) and the surface of the cells. The invention therefore relates to sulfated polysaccharides, preferably glycosaminoglycans, for use as a medicament for the inhibition of the physical interaction between the cell surface and platelets in the treatment of a medical disorder associated with unwanted cell growth and/or proliferation. In vitro methods for modulating the physical interaction between platelets (thrombocytes) and the surface of the cells in order to modulate cell proliferation are also encompassed by the invention. The invention therefore relates to the inhibition of the interaction between the cell surface and platelets for the inhibition of cell growth, and an enhancement of the interaction between platelets and the surface of the cell in order to enhance cell growth.

Australia
* Sulfated polysaccharides for use in the treatment of cancer
Patent number 2014339000

U.S.A.
* MODULATION OF THE PHYSICAL INTERACTION BETWEEN PLATELETS AND THE CELL SURFACE EFFECTING CELL PROLIFERATION
Patent number10098906
Issue date 10/16/2018

Japan

* MODULATION OF THE PHYSICAL INTERACTION BETWEEN PLATELETS AND THE CELL SURFACE EFFECTING CELL PROLIFERATION"
Patent number 2016-525966

Canada

* MODULATION OF THE PHYSICAL INTERACTION BETWEEN PLATELETS AND
THE CELL SURFACE EFFECTING CELL PROLIFERATION

Patent Nr. 2,926,888